503045-59-8

Usage

Uses

Used in Pharmaceutical Research and Development:
6-Chloro-3-Iodo (1H) Indazole is used as a chemical intermediate in the synthesis of pharmaceutical compounds. Its distinctive structure with both chloro and iodo substituents allows for versatile chemical reactions, making it a valuable component in the development of new drugs.
Used in Chemical Synthesis:
6-Chloro-3-Iodo (1H) Indazole serves as a key building block in the synthesis of various organic compounds. Its unique structure enables it to participate in a range of chemical reactions, facilitating the creation of new molecules with specific properties and applications.
Used in Material Science:
6-Chloro-3-Iodo (1H) Indazole can be utilized in the development of novel materials with specific properties. Its ability to interact with other substances and undergo various chemical reactions allows for the creation of materials with tailored characteristics for use in different industries.
Used in Analytical Chemistry:
6-Chloro-3-Iodo (1H) Indazole can be employed as a reagent or reference compound in analytical chemistry. Its distinctive structure and properties make it suitable for use in various analytical techniques, such as chromatography, spectroscopy, and titration, to study and characterize other substances.
Used in Environmental Research:
6-Chloro-3-Iodo (1H) Indazole may be used in environmental research to study the behavior and fate of similar compounds in the environment. Understanding its interactions with other substances and its potential impact on ecosystems can help in assessing the environmental risks associated with its use and disposal.
Used in Academic Research:
6-Chloro-3-Iodo (1H) Indazole is a valuable compound for academic research, particularly in the fields of organic chemistry, medicinal chemistry, and materials science. Its unique structure and potential applications provide opportunities for exploring new chemical reactions, synthesizing novel compounds, and investigating the properties of this and related compounds.

Upstream product

• 698-25-9 6-chloro-1H-indazole 
• 61072-56-8 4-chloro-2-fluorobenzaldehyde 
• 95-79-4 5-chloro-2-methyl-benzenamine 

Downstream Products

• 717134-47-9 methyl 6-chloro-1H-indazole-3-carboxylate 
• 885278-30-8 6-chloro-1H-indazole-3-carbonitrile 
• 13097-04-6 6-chloro-3-phenyl-1H-indazole 

Relevant academic research and scientific papers

Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors

Herein we report the discovery of a novel series of highly potent and selective mitogen-activated protein kinase kinase 4 (MEK4) inhibitors. MEK4 is an upstream kinase in MAPK signaling pathways that phosphorylates p38 MAPK and JNK in response to mitogenic and cellular stress queues. MEK4 is overexpressed and induces metastasis in advanced prostate cancer lesions. However, the value of MEK4 as an oncology target has not been pharmacologically validated because selective chemical probes targeting MEK4 have not been developed. Optimization of this series via structure–activity relationships and molecular modeling led to the identification of compound 6 ff (4-(6-fluoro-2H-indazol-3-yl)benzoic acid), a highly potent and selective MEK4 inhibitor. This series of inhibitors is the first of its kind in both activity and selectivity and will be useful in further defining the role of MEK4 in prostate and other cancers.

HISTONE DEMETHYLASE INHIBITORS

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrrolopyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject com

Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold

A novel series of 3-(pyrrolopyridin-2-yl)indazole derivatives were synthesized and biologically evaluated for their anti-proliferative effects on five human cancer cell lines. As a result, all of them exhibited vigorous potency against HL60 cell line with IC50 values ranging from singe digital nanomolar to micromolar level. Besides, a majority of them displayed modest to good antiproliferative activities against the other four cell lines, including KB, SMMC-7721, HCT116, and A549. Particularly, compound 2y, as the most distinguished one in this series, demonstrated IC50 values of 8.3 nM and 1.3 nM against HL60 and HCT116 cell lines, respectively. Afterwards, for exploring the molecular target, compounds2d, 2g and 2y were further selected to evaluate the inhibitory activities against a panel of kinases. Finally, they were identified to be targeting Aurora A kinase with significant selectivity over other kinases, such as CHK1, CDK2, MEK1, GSK3β, BRAF, IKKβ and PKC.

Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors

We describe the discovery of several pyrrolopyrazines as potent and selective Syk inhibitors and the efforts that eventually led to the desired improvements in physicochemical properties and human whole blood potencies. Ultimately, our mouse model revealed unexpected toxicity that precluded us from further advancing this series.

PYRROLOPYRAZINE KINASE INHIBITORS

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome

Using a structure based design approach we have identified a series of indazole substituted pyrrolopyrazines, which are potent inhibitors of JAK3. Intramolecular electronic repulsion was used as a strategy to induce a strong conformational bias within the ligand. Compounds bearing this conformation participated in a favorable hydrophobic interaction with a cysteine residue in the JAK3 binding pocket, which imparted high selectivity versus the kinome and improved selectivity within the JAK family.

SOLUBLE GUANYLATE CYCLASE ACTIVATORS

A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ("cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I , or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the above mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof

Synthesis of 3-indazolecarboxylic esters and amides via Pd-catalyzed carbonylation of 3-iodoindazoles

A straightforward and effective procedure for the preparation of 1H-indazole-3-carboxylic acid esters and amides was developed. A series of functionalized 3-iodoindazoles were subjected to Pd-catalyzed carbonylations in the presence of methanol or amines,